<DOC>
	<DOCNO>NCT00453427</DOCNO>
	<brief_summary>The primary objective study : 1. establish safety dose limit toxicity combine alemtuzumab CHOP chemotherapy patient newly diagnose aggressive T-cell lymphoma ; 2. measure pharmacokinetics alemtuzumab use different subcutaneous dos schedule . This determine dose high achievable drug level acceptable toxicity worthy investigation . The secondary objective : 1. establish efficacy combination alemtuzumab CHOP chemotherapy ; 2. measure effect combination alemtuzumab CHOP chemotherapy T-cell reconstitution cytomegalovirus ( CMV ) reactivation .</brief_summary>
	<brief_title>Alemtuzumab CHOP Chemotherapy Aggressive Histological Peripheral T-Cell Lymphomas</brief_title>
	<detailed_description>Aggressive peripheral T-cell lymphoma account 10 - 15 % Non-Hodgkin 's Lymphoma ( NHL ) present adverse prognostic feature aggressive histology B-cell NHL . Correspondingly , overall poor prognosis B-cell lymphoma , achieve low complete response rate , freedom progression overall survival conventional anthracycline-based CHOP ( cyclophosphamide , doxorubicin , vincristine prednisone ) chemotherapy . Fewer 30 % patient cured therapy . New treatment replicate improve survival chemo-immunotherapy B-cell lymphoma need . Alemtuzumab humanize murine antibody bind ubiquitous lymphoid marker CD52 efficacious ( monotherapy ) relate lymphoproliferative disease . Combining alemtuzumab CHOP chemotherapy may improve response rate outcomes patient sub-type NHL . The combination must first test dose escalation fashion establish dosage doublet potential overlapping exaggerated toxicity . This prospective , multi-center , open label Phase I-II study enroll 22-84 patient newly diagnose previously untreated aggressive histology peripheral T-cell lymphoma . In Phase I component , patient sequentially enrol cohort three patient treat increase dos alemtuzumab administer combination standard CHOP chemotherapy . When maximal tolerate dose determine , dose schedule test 46 patient use Simon two stage Phase II design .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Patients age 18 year age old time enrollment , Histologically prove centrally review CD52+ Tcell NHL Stages 24 include follow nodal extranodal subtypes : Nodal : Peripheral Tcell lymphoma otherwise specify ( PTL NOS ) Angioimmunoblastic lymphadenopathy ( AILD ) ALK 1 negative anaplastic large cell NHL Extranodal : Hepatosplenic Enteropathyassociated Panniculitic Previous treatment chemotherapy radiation exception 1 cycle CHOP chemotherapy . Expected survival &lt; 4 month . ECOG performance status &gt; 3 . Inadequate haematologic function ( Hb &lt; 85g/L , ANC &lt; 1000/mm3 , platelet count &lt; 75,000/mm3 ) unless directly attributable NHL . Inadequate hepatic function ( total bilirubin &gt; 35μmol/L , alkaline phosphatase &gt; 2x UL normal , AST/ALT &gt; 2x UL normal ) Inadequate renal function ( serum creatinine &gt; 130μmol/L ) , unless directly attributable NHL . Nonmeasurable nonevaluable disease , accord criterion Cheson et al49 . Geographically inaccessible followup Known hypersensitivity study drug Serious illness may interfere subject compliance , determination causality adverse event would compromise protocol objective . Known HIV positivity preexist immunodeficiency ( e.g. , postorgan transplant ) . Known CNS involvement lymphoma ( test investigate CNS involvement require clinically indicate ) . Pregnant lactating woman . Women childbearing potential use effective contraception . Men reproductive potential use effective contraception . Previous malignancy within last 5 year exception cervical carcinoma situ non melanoma skin cancer . Nasal natural killer ( NK ) Tcell NHL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>PTL NOS</keyword>
	<keyword>AILD</keyword>
	<keyword>NHL</keyword>
	<keyword>CHOP</keyword>
</DOC>